MME and early-onset autosomal dominant Alzheimer disease: For instance, in an in vivo model of Alzheimer’s disease, exosomes containing RVG peptides and a genetically engineered CD10 variant demonstrated enhanced efficacy in targeting amyloid-beta aggregates and improved hippocampal delivery.